Precipio (NasdaqCM:PRPO) Q3 2025 Earnings Call November 17, 2025 05:00 PM ET Company ParticipantsIlan Danieli - CEOOperatorWelcome to the Precipio III Quarter 2025 Shareholder Update Conference call. All participants will be in listen-only mode. If you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place u ...

Financial Data and Key Metrics Changes - The company reported gross revenues of BRL 4.9 billion, representing a 9% growth year over year and a 6% growth quarter over quarter [19] - Net income reached BRL 1.3 billion, a 12% growth year over year and a 1% increase quarter over quarter [23] - The return on equity (ROE) was 23%, flat year over year, while the capital ratio stood at 21.2%, an increase of 180 basis points quarter over quarter [7][24] Business Line Data and Key Metrics Changes - Retail revenues reached BRL 3.7 billion, representing 6% growth year over year and 4% growth quarter over quarter [19] - Corporate and industry services achieved a record performance of BRL 729 million, with 32% growth year over year and 33% growth quarter over quarter [21] - Life insurance retail premium posted a 25% growth year over year, while retirement plans client assets grew 15% year over year, reaching BRL 90 billion [14] Market Data and Key Metrics Changes - The company reported BRL 20 billion in retail net new money and BRL 9 billion in corporate and institutional, totaling BRL 5 billion lower than last year but three times higher than last quarter [8] - The company maintained a 10% market share in capital markets distribution, with a robust pipeline of fixed income offerings [15] Company Strategy and Development Direction - The company aims to become the leader in investments in Brazil by enhancing client service and introducing new products, including a new app and credit card offerings [3][10] - The strategy includes democratizing access to high-quality wealth planning services, previously reserved for high-net-worth clients [10][12] - The company is focused on improving its investment platform and enhancing client experience through advisor initiatives [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 but emphasized commitment to evolving the business for growth and profitability [4] - The outlook for the wholesale banking segment remains positive, with expectations for continued strong performance in Q4 [31] - Management indicated that while achieving the 10% revenue growth target for 2025 may be challenging, they remain optimistic about future growth [82] Other Important Information - The company repurchased BRL 2 billion in shares in 2025, with a new BRL 1 billion buyback program announced [24] - The company plans to pay a dividend of BRL 500 million in 2025, representing a 50% payout ratio based on net income [24] Q&A Session Summary Question: Expectations for wholesale business performance in Q4 - Management expects good performance in the wholesale banking segment for Q4, with a strong second half of the year compared to the first half [31][33] Question: Details on the strategy to increase the warehousing book - The strategy involves holding high-quality assets and increasing the warehouse book to sell to retail clients in the following year [33] Question: Clarification on corporate revenues and hedging strategy - Corporate revenues are tied to DCM activity, with hedging solutions being a significant driver [39] Question: Insights on fixed income revenue contraction despite AUC growth - The contraction in fixed income revenues is attributed to a shift in the mix towards lower take rates and shorter durations [46] Question: Impact of new hires on advisor numbers - The decrease in the number of advisors is due to the conversion of IFAs into employees and a focus on hiring higher-quality advisors [52] Question: Explanation for the reduction in financial expenses - The reduction in financial expenses is linked to a geographic shift in debt management, with cheaper bank debt replacing corporate debt [54] Question: Future guidance on EBIT margin - Management believes achieving the EBIT margin guidance is still possible, but it may take until the end of next year to realize [62]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258, with a 34-location increase, and the annual customer count expanded to approximately 6.5 million [2] - Financial performance showed signs of recovery, with sales previously affected by restructuring and franchise fees, but now supported by an increase in point-related revenues [3] - Operating income and net income improved due to a decline in racing-related costs, including share-based compensation expenses [3] Business Line Data and Key Metrics Changes - The average revenue per customer visit is recovering due to pricing and promotion initiatives, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D and expanding unique service offerings through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The financial impact of the new BREATH initiative in Thailand is expected to be minimal in the near term, with plans to expand into other Asian countries after proof of concept [10] Company Strategy and Development Direction - The company aims to strengthen its overall competitiveness and achieve sustainable growth through strategic acquisitions and partnerships, particularly in the aesthetic medical field [5][20] - The M&A strategy is divided into domestic and global perspectives, focusing on clinic field acquisitions in Japan and exploring investment opportunities in the US market [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining the positive momentum observed in Q3, with expectations for stable financial performance in Q4 and the following year [11][22] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [22][26] Other Important Information - The company is working on improving share liquidity through new share issuance and potential share buybacks, acknowledging that the current share price is too low [6][24] - Dividend payments are being considered as a way to attract new investors, although the company prioritizes capital allocation towards strategic initiatives [25] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a franchise fee division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with financial performance expected to continue improving [8] Question: Could you elaborate on the balance sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [9] Question: What is the expected impact of the new BREATH initiative in Thailand? - The near-term financial impact will be minimal as the company conducts proof of concept for laser treatments, with plans for future expansion into other Asian markets [10] Question: What is the expectation for organic growth going forward? - The company anticipates maintaining the positive momentum from Q3, with expectations for stable financial performance in the upcoming quarters [11] Question: Can you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through enhanced sales of Waku products at SBC clinics and joint development of pharmaceutical and medical devices [12][15] Question: Can you comment on the latest status of US business development efforts? - The company is in the phase of understanding the US market and seeking strong partners to leverage its strengths from Japan, with cautious plans for future clinic development [17][18] Question: What are the expectations for M&A going forward? - The M&A strategy will focus on domestic clinic acquisitions and exploring investment opportunities in the global market, particularly in the US [20] Question: How do you plan to improve the liquidity situation? - Plans include increasing free float through new share issuance and potential share buybacks, acknowledging the current low share price [24] Question: Do you think about the dividend going forward? - Dividend payments are considered to attract new investors, but the company prioritizes capital allocation towards growth opportunities [25] Question: Do you have any plan to disclose financial guidance going forward? - The company is considering providing financial guidance in the near future [26]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258 clinics, with an annual customer base expanding to approximately 6.5 million [2][3] - Financial performance showed signs of recovery, with operating income and net income benefiting from a decline in racing-related costs and an increase in point-related revenues [3][4] Business Line Data and Key Metrics Changes - The average revenue per customer visit is recovering due to pricing and promotion strategies, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D capabilities through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The company is exploring proof of concept (POC) initiatives in Thailand, with plans to expand into other Asian markets like Malaysia and Indonesia [11] Company Strategy and Development Direction - The company aims to strengthen its overall competitiveness and achieve sustainable growth through strategic partnerships and acquisitions, particularly in the aesthetic medical and clinical industries [20] - The U.S. market entry strategy involves forming strong partnerships and leveraging learnings from the Japanese market, while being cautious about direct replication of the business model [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining positive momentum in financial performance, expecting stable growth in Q4 and the following year [12][21] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [21][25] Other Important Information - The company is working on improving liquidity through measures such as new share issuance and potential share buybacks, acknowledging the current low share price [6][23] - Dividend payments are being considered as a way to attract new investors, although the focus remains on capital allocation for strategic initiatives [24] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a Franchise Fee Division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with expectations of continued positive trends [9] Question: Could you elaborate on the Balance Sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [10] Question: What is your expectation for organic growth going forward for both breadth and revenue? - The company expects to maintain positive momentum seen in Q3, with stable financial performance anticipated in Q4 and next year [12] Question: Could you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through enhanced sales of Waku products at SBC clinics and joint development of pharmaceutical and medical devices [15][16] Question: Can you comment on the latest status of your U.S. business development efforts? - The company is in a phase of understanding the U.S. market and seeking strong partners, with plans for future growth and expansion once comfortable [17][18] Question: What do you mean by more stable financial performance in Q4 and 2026? - Management confirmed expectations for revenue growth but could not provide specific numbers at this time [21] Question: How do you think about improving the liquidity situation? - The company is considering new share issues and share buybacks to increase free float and address low share prices [23] Question: Do you have any plan to disclose financial guidance or performance guidance going forward? - The company is actively considering providing financial guidance in the near future [25]

XP (NasdaqGS:XP) Q3 2025 Earnings Call November 17, 2025 05:00 PM ET Company ParticipantsAndré Parize - Head of Investor RelationsVictor Mansur - CFOThiago Maffra - CEOConference Call ParticipantsMario Pierry - AnalystThiago Batista - AnalystGustavo Schroden - AnalystEduardo Rosman - AnalystTito Labarta - AnalystYuri Fernandes - AnalystDaniel Vaz - AnalystMarcelo Mizrahi - AnalystAndré ParizeGood evening, everyone. I'm André Parize, Investor Relations Officer at XP, and it's a pleasure to be here with you t ...

Precipio (NasdaqCM:PRPO) Q3 2025 Earnings Call November 17, 2025 05:00 PM ET Company ParticipantsIlan Danieli - CEOOperatorWelcome to the Precipio third quarter 2025 shareholder update conference call. All participants will be in listen-only mode. If you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place ...

Financial Data and Key Metrics Changes - For Q3 2025, the company achieved a positive adjusted EBITDA of nearly $500,000 and generated over $250,000 in cash from operations, marking a significant financial milestone [3][15] - Revenue for Q3 reached $6.8 million, representing a 30% increase year-over-year and a 20% increase quarter-over-quarter [6] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in Q2 2025, indicating a swing of over $500,000 in just one quarter [15] - Cash generated from operations was $285,000, a positive cash swing of $433,000 compared to a cash burn of $148,000 in the previous quarter [15] Business Line Data and Key Metrics Changes - The Pathology Services Division reported revenue growth from $5 million in Q2 to $6 million in Q3, a 20% increase, driven by new customer acquisitions [7] - The Products Division experienced a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3, primarily due to increased utilization from existing customers and new product introductions [9][10] - Gross margins improved from 43% to 44% overall, with the Pathology Services Division increasing margins from 43% to 46% [10][15] Market Data and Key Metrics Changes - The company has seen a tripling of its share price since the beginning of 2023, reflecting market confidence in its financial performance and growth strategy [5] - The company is experiencing a strong sales funnel with several new customers in trial phases, indicating a robust market demand for its services [7] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated from operations to accelerate growth [3][5] - Future priorities include driving double-digit growth in both divisions, expanding margins, and reinvesting cash into growth initiatives [17] - The company aims to achieve a gross margin exceeding 50% by mid-2026 as both divisions scale up [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's self-sustaining business model, stating that it will no longer depend on outside capital for operations [16] - The company anticipates that increased market capitalization will present new strategic opportunities for growth and partnerships [16] - Management emphasized the importance of their mission, linking financial success to improved patient care outcomes [17] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [16] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [11][14] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Data and Key Metrics Changes - The company reported total client assets of BRL 1.9 trillion, reflecting a 16% year-over-year growth [4] - Gross revenues reached BRL 4.9 billion, representing a 9% growth year over year [5][18] - EBIT increased by 10% year over year to BRL 1.3 billion [5] - The return on equity (ROE) was 23%, remaining flat year over year [6] - Diluted EPS grew by 13% year over year, reaching BRL 2.47 per share [24] Business Line Data and Key Metrics Changes - Retail revenues amounted to BRL 3.7 billion, showing a 6% growth year over year [18] - Corporate and industry services achieved a record BRL 729 million in revenues, marking a 32% growth year over year [18] - Life insurance retail premiums grew by 25% year over year [13] - Credit revenues increased by 11% year over year, reaching BRL 83 million in net interest income [13] Market Data and Key Metrics Changes - Retail net new money was BRL 20 billion, a decrease of BRL 5 billion compared to the previous year but three times higher than the last quarter [7] - The company maintained a 10% market share in capital markets distribution [15] - The wholesale bank maintained a leadership position with a 17% market share [16] Company Strategy and Development Direction - The company aims to become the leader in investments in Brazil by enhancing client service and introducing new products [3][10] - A focus on high-quality wealth planning services for clients with varying asset levels is being emphasized [10] - The company is transitioning to a fee-based model, which currently accounts for 21% of total retail assets under custody [11] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the challenges faced in 2025 but expressed commitment to evolving the business for growth and profitability [4] - The company anticipates continued growth in retail net new money, targeting around BRL 20 billion per quarter [9] - Management highlighted the importance of maintaining a conservative risk profile despite strong performance in wholesale banking [25] Other Important Information - The company repurchased BRL 2 billion in shares in 2025, with a new buyback program of BRL 1 billion announced [23] - A dividend of BRL 500 million is planned for 2025, representing a 50% payout ratio based on net income [23] Q&A Session Summary Question: Expectations for wholesale business performance in Q4 - Management expects good performance in Q4, with stronger results anticipated compared to the first half of the year [26][27] Question: Details on the strategy to increase the warehousing book - The strategy involves holding high-quality assets and managing credit spread volatility effectively [27] Question: Clarification on corporate revenue increase - Corporate revenues are closely tied to debt issuance and hedging solutions, with strong performance expected to continue [30][44] Question: Insights on retail revenue growth despite fixed income contraction - The contraction in fixed income revenues is attributed to a shift in product mix and shorter durations affecting take rates [31][33] Question: Impact of workdays on revenues - Business days positively impacted floating and trading volumes, offsetting declines in equities and fixed income [49] Question: Use of AI in client advisory services - The company is leveraging AI to enhance advisor productivity and improve client service, particularly for lower-income clients [51]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258, with a 34-location increase, and the annual customer count expanded to approximately 6.5 million [2] - Financial performance showed signs of recovery, with sales previously affected by restructuring and franchise fee division, but now supported by an increase in point-related revenues [3][4] - The decline in racing-related costs, including share-based compensation expenses, contributed to improvements in both operating income and net income [3] Business Line Data and Key Metrics Changes - The average revenue per customer visit is showing signs of recovery due to pricing and promotion initiatives, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D and expanding service offerings through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The financial impact of the new BREATH initiative in Thailand is expected to be minimal in the near term as the company conducts proof of concept trials [10] Company Strategy and Development Direction - The company aims to strengthen its competitiveness and achieve sustainable growth through strategic acquisitions and partnerships, particularly in the aesthetic medical field [5][20] - The M&A strategy is divided into domestic and global perspectives, focusing on clinic acquisitions in Japan and exploring investments in the global market, especially in the US [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining the positive momentum observed in Q3 2025, with expectations for stable financial performance in Q4 and 2026 [11][22] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [22][26] Other Important Information - The company is working on improving liquidity by increasing free float shares and considering new share issuances and share buybacks [24] - Dividend payments are being considered as a way to attract new investors, although the company prioritizes capital allocation towards strategic initiatives [25] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a franchise fee division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with financial performance expected to continue improving [8] Question: Could you elaborate on the balance sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [9] Question: What is your expectation for organic growth going forward for both breadth and revenue? - The company expects to maintain the positive momentum seen in Q3, with more stable financial performance anticipated in Q4 and next year [11] Question: Can you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through strengthening sales of Waku products at SBC clinics and jointly developing pharmaceutical and medical devices [12][14] Question: Can you comment on the latest status of your US business development efforts? - The company is in the phase of understanding the US market and seeking strong partners to leverage its strengths from Japan [17] Question: What do you mean by more stable financial performance in Q4 and 2026? - Management confirmed expectations for a return to revenue growth but could not provide specific numbers at this time [22] Question: How do you think about improving the liquidity situation? - The company aims to increase free float shares and is considering share buybacks due to the current low share price [24] Question: Do you have any plan to disclose financial guidance or performance guidance going forward? - The company is actively considering providing financial guidance in the near future [26]

Financial Data and Key Metrics Changes - For the first quarter of fiscal 2026, the company reported revenue of CAD 19.2 million, an increase of approximately 27% compared to CAD 15.1 million in the same period last year [11][12] - Gross margin improved significantly from 27% to 45% year-over-year [12][27] - Net income for the quarter was CAD 1 million or CAD 0.03 per basic share, compared to a net loss of CAD 26.5 million or CAD 0.87 per basic share in the same quarter of fiscal 2025 [13] Business Line Data and Key Metrics Changes - Development fee revenue for Q1 fiscal 2026 was CAD 3.4 million, a notable increase from zero in the same period last year, reflecting higher development activities [11][12] - Revenue from EPC services increased slightly to CAD 11.9 million, up approximately 1% from the prior year [11] - Independent Power Producer (IPP) revenue grew to CAD 3.8 million, an 18% increase from CAD 3.3 million in the prior fiscal year [5][12] Market Data and Key Metrics Changes - The company is currently managing projects representing approximately 104 MW of solar and 44 MWh of battery energy storage expected to reach notice to proceed within 12 months [4] - The company has announced several projects in the U.S. and Canada, including a fully operational 3.8 MW solar power plant in New York and a 4.99 MW battery energy storage system in Ontario [6][9] Company Strategy and Development Direction - The company is focusing on expanding its IPP portfolio and advancing its development pipelines, particularly in battery storage project development [15][18] - The company is also entering the data center market and exploring environmentally friendly solutions for data centers powered by solar energy [20][21] - A strategic development agreement has been established with Intellistic Technologies to integrate AI and blockchain technologies into the company's operations [23] Management's Comments on Operating Environment and Future Outlook - Management noted that the renewable energy industry has faced significant headwinds but sees a clearer path forward due to supportive government policies [16][17] - The demand for battery storage is expected to increase due to rising electricity prices and the need for power reliability [32] - The company remains optimistic about the future of battery storage and solar energy, citing technological advancements and cost reductions [20][32] Other Important Information - The company has secured favorable financing terms and continues to maintain a strong cash position of approximately CAD 13.3 million [15] - The company is actively engaging with local communities to address concerns related to battery storage projects, which has caused some permitting delays [30][31] Q&A Session Summary Question: Factors driving the company's gross margin increase from 27% to 45% - Management attributed the increase to effective field management and procurement strategies, noting that the company has shifted to domestic procurement to maintain cost advantages [26][27] Question: Delays impacting key projects and outlook - Management acknowledged permitting delays for the SFFO6 project and interconnection challenges for other projects, but remains positive about the battery storage market due to increasing demand and electricity prices [29][32] Question: Progress in monetizing and securing safe harbor for US pipelines - Management indicated that the company is focusing on project-specific long lead items to meet new guidelines and ensure timely project delivery [34][35]